Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: J Immunol. 2011 Oct 31;187(11):5921–5930. doi: 10.4049/jimmunol.1100746

Fig. 5.

Fig. 5

IL-10 and IFN-γ Elispot assays from DQ8 type 1 diabetic individuals and controls. (A) IL-10 Elispot in type 1 diabetic subjects (n=14) showing an increase in IL-10 spots with glyphosine and B:9–23 peptide compared to B:9–23 peptide alone. (B) IFN-γ Elispot showing no change in number when glyphosine is added to culture with or without B:9–23 peptide. (C) IL-10 and (D) IFN-γ Elispots from nondiabetic DQ8 controls (n=8) showing no change in spot number with glyphosine. All patients produced IFN-γ in response to a tetanus toxin peptide (used as a positive control) which did not change in response to glyphosine. Each data point represents the mean spot number from triplicate wells for an individual. Wilcoxon matched pairs test was used to compare means between groups and p values are labeled on graphs for ease of comparison.